08:47 AM EDT, 09/10/2025 (MT Newswires) -- Lucid Diagnostics ( LUCD ) said Wednesday that it has priced its underwritten public offering of 25 million shares at $1 per share for gross proceeds of $25 million.

The company said it has granted the underwriters a 30-day option to purchase up to an additional 3.8 million shares.

Proceeds from the offering, expected to close on Thursday, will be used for working capital and general corporate purposes, the company said.

Shares of the company were down 16% in recent Wednesday premarket activity.